2021-01-10,Dyne Therapeutics Myotonic Dystrophy Type 1 Program Achieves Robust RNA Knock Down of Toxic Human Nuclear DMPK in Preclinical Study
2021-01-05,Dyne Therapeutics to Present at 39th Annual J.P. Morgan Healthcare Conference
2020-12-08,Cerevance Appoints David Lubner to Board of Directors
2020-11-09,Dyne Therapeutics to Present at Upcoming Investor Conferences
2020-11-05,Dyne Therapeutics Reports Third Quarter 2020 Financial Results and Recent Highlights
2020-10-09,Janus Henderson and PMV Pharmaceuticals See Activist Action
2020-09-21,Dyne Therapeutics Announces Closing of Initial Public Offering
2020-09-16,Dyne Therapeutics Announces Pricing of Initial Public Offering
2019-12-13,"Vistra Operations Company LLC -- Moody's upgrades Vistra's CFR to Ba1 from Ba2, outlook positive"
